The Food and Drug Administration’s Center for Devices and Radiological Health (CDRH) announced this month that for the second year in a row, its premarket review program had no backlog of 510(k)s, premarket approval applications, or PMA supplements
The Food and Drug Administrations Center for Devices and Radiological Health (CDRH) announced this month that for the second year in a row, its premarket review program had no backlog of 510(k)s, premarket approval applications, or PMA supplements for fiscal year 1998.
Average total review time for 510(k) applications was 114 days an improvement over 130 in 1997 and 145 in 1996. Median review time for 510(k)s that cleared in fiscal year 1998 was 83 days. CDRH cleared 46 PMAs in 1998, according to the agency. The average review time of PMAs from submission to approval was roughly 12 months, 25% less than fiscal year 1997 and 50% less than fiscal year 1996. The median total time the CDRH took to clear PMAs in 1998 was about nine months.
The program attributed improved clearance times to more companies consulting with the FDA as they plan clinical studies. They also credited pilot management initiatives the CDRH implemented this year.
Study: AI Boosts Ultrasound AUC for Predicting Thyroid Malignancy Risk by 34 Percent Over TI-RADS
February 17th 2025In a study involving assessment of over 1,000 thyroid nodules, researchers found the machine learning model led to substantial increases in sensitivity and specificity for estimating the risk of thyroid malignancy over traditional TI-RADS and guidelines from the American Thyroid Association.
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.